Search for content, post, videos

AI Medical Technology raises USD 1 million

The company has announced the successful closure of an oversubscribed bridge financing round.

Funding was provided by existing investors, such as Northern Venture CapSek, and new shareholders. The money will be used to support ongoing regulatory efforts and development of the company’s AI-driven support tool, Dermalyser, a clinically validated decision support tool for the diagnosis of malignant melanomas.

“I am delighted to be raising more money to support the ongoing development of Dermalyser. To have yet another oversubscribed round just shows that Dermalyser is in a league of its own when it comes to new diagnostic tools for skin cancer. With fantastic clinical results, excellent user feedback, and a passionate team who really believe in making a difference, we will continue to move from strength to strength. Our roadmap is now consolidated – we will raise more funds in a Series A round this year and plan for an IPO in 2027-2028,” says Christoffer Ekström, CEO of AI Medical Technology.

Photo of Christoffer Ekström